Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
Canada
/ epidemiology
Cohort Studies
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
/ therapeutic use
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
/ agonists
Glucose
Humans
Hypoglycemic Agents
/ pharmacology
Sodium
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Symporters
/ therapeutic use
United Kingdom
/ epidemiology
Type 2 diabetes
dipeptidyl peptidase 4 inhibitors
glucagon-like peptide 1 receptor agonists
sodium-glucose co-transporter 2 inhibitors
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
29 Sep 2022
29 Sep 2022
Historique:
received:
14
04
2022
accepted:
01
09
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Characteristics of patients using newer 2 We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018. Our cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean ± SD: 56.7 ± 12.2 years) than new users of DPP-4i (67.8 ± 12.3 years) or SGLT-2i (64.4 ± 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%). Although SGLT-2i, DPP-4i, and GLP-1 RAs are recommended as 2
Sections du résumé
BACKGROUND
BACKGROUND
Characteristics of patients using newer 2
METHODS
METHODS
We conducted a multi-database cohort study using administrative health databases from 7 Canadian provinces and the UK Clinical Practice Research Datalink. We assembled a base cohort of antidiabetic drug users between 2006 and 2018, from which we constructed 3 cohorts of new users of SGLT-2i, DPP-4i, and GLP-1 RA between 2016 and 2018.
RESULTS
RESULTS
Our cohorts included 194,070 new users of DPP-4i, 166,722 new users of SGLT-2i, and 27,719 new users of GLP-1 RA. New users of GLP-1 RA were more likely to be younger (mean ± SD: 56.7 ± 12.2 years) than new users of DPP-4i (67.8 ± 12.3 years) or SGLT-2i (64.4 ± 11.1 years). In Canada, new users of DPP-4i were more likely to have a history of coronary artery disease (22%) than new users of SGLT-2i (20%) or GLP-1 RA (15%).
CONCLUSION
CONCLUSIONS
Although SGLT-2i, DPP-4i, and GLP-1 RAs are recommended as 2
Identifiants
pubmed: 36175881
doi: 10.1186/s12902-022-01140-1
pii: 10.1186/s12902-022-01140-1
pmc: PMC9520836
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Symporters
0
Glucagon-Like Peptide 1
89750-14-1
Sodium
9NEZ333N27
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Investigateurs
Samy Suissa
(S)
Colin R Dormuth
(CR)
Brenda R Hemmelgarn
(BR)
Jacqueline Quail
(J)
Dan Chateau
(D)
J Michael Paterson
(JM)
Jacques LeLorier
(J)
Adrian R Levy
(AR)
Pierre Ernst
(P)
Kristian B Filion
(KB)
Robert W Platt
(RW)
Ingrid S Sketris
(IS)
Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2018 Aug 25;392(10148):637-649
pubmed: 30122305
Diabetes Res Clin Pract. 2018 Sep;143:88-100
pubmed: 29944969
Open Med. 2012 Oct 30;6(4):e134-40
pubmed: 23687528
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
J Am Coll Cardiol. 2018 Dec 18;72(24):3200-3223
pubmed: 30497881
Lancet. 2009 Nov 7;374(9701):1606-16
pubmed: 19853906
JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587
pubmed: 30456329
Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):278-86
pubmed: 26648236
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854
pubmed: 31495651
Diabetes Care. 2019 Jan;42(Suppl 1):S182-S183
pubmed: 30559242
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062